2023 World Conference on Lung Cancer (Posters)-P1.21. Major Pathologic Response after Neoadjuvant Therapy in NSCLC: Predicting Better Outcomes with High Interobserver Agreement

P1.21. Major Pathologic Response after Neoadjuvant Therapy in NSCLC: Predicting Better Outcomes with High Interobserver Agreement - PDF(Abstract)

Back to course

Pdf Summary

This presentation discusses the use of major pathologic response (MPR) as a predictor of outcomes in patients with non-small cell lung cancer (NSCLC) who underwent surgery after neoadjuvant therapy. MPR refers to the percentage of viable tumor after treatment. The study aimed to assess the interobserver agreement in measuring MPR in NSCLC patients.<br /><br />The researchers reviewed slides from surgical specimens of 66 patients treated with neoadjuvant therapy between 2009 and 2014. Three observers evaluated the area-weighted average percentages of viable tumor, necrosis, and stroma according to the International Association for the Study of Lung Cancer (IASLC) recommendations. Interobserver agreement for MPR and viable tumor percentage was evaluated using statistical methods.<br /><br />The results showed that 13 of the 66 patients (19.7%) had MPR (defined as 10% or less viable tumor) based on the average viable tumor percentage rated by the three observers. The interobserver agreement for MPR was high, with a Fleiss' kappa coefficient of 0.877. The correlation between MPR and long-term outcomes was analyzed using Kaplan-Meier methods and Cox proportional hazard analysis. The patients with MPR had improved overall survival, progression-free survival, and lung cancer-specific cumulative incidence of death.<br /><br />The study concludes that there is high interobserver agreement in evaluating MPR according to IASLC recommendations. MPR is associated with better clinical outcomes in NSCLC patients who underwent neoadjuvant therapy and surgery.<br /><br />Keywords for this study include major pathologic response, neoadjuvant therapy, and interobserver agreement.

Asset Subtitle

Sungjin Kim

Meta Tag

Speaker Sungjin Kim

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

major pathologic response

neoadjuvant therapy

non-small cell lung cancer

NSCLC

surgery

interobserver agreement

viable tumor

necrosis

stroma

IASLC recommendations